Sign In
Buy ATRA
$9.63
-0.270 (-2.73%)
At Close: Jun 03, 2026
Stocks To Watch: Tech Reboots And Eyes On Lululemon, Peloton & GameStop
08:21am, Saturday, 05'th Sep 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
Tracking Seth Klarman's Baupost Group Holdings - Q2 2020 Update
08:00am, Saturday, 15'th Aug 2020
Seth Klarman’s 13F portfolio value increased from $6.77B to $8.01B this quarter. Baupost Group increased Atara Biotherapeutics while dropping Cheniere Energy.
Genomic Medicine: Summer 2020 Update
09:36am, Thursday, 13'th Aug 2020
FDA approvals, new guidance statements, and RMAT requests all show the pace of genomics is accelerating.
Did Hedge Funds Make The Right Call On Atara Biotherapeutics Inc (ATRA) ?
01:53pm, Wednesday, 12'th Aug 2020
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that sm
Cowen & Co. Remains a Buy on Atara Biotherapeutics (ATRA) - Markets
04:03pm, Sunday, 09'th Aug 2020
In a report issued on August 6, Phil Nadeau from Cowen & Co. maintained a Buy rating on Atara Biotherapeutics
H.C. Wainwright Keeps a Buy Rating on Atara Biotherapeutics (ATRA) - Markets
10:38am, Thursday, 06'th Aug 2020
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Atara Biotherapeutics (ATRA – Research
Canaccord Genuity Sticks to Its Buy Rating for Atara Biotherapeutics (ATRA) - Markets
10:35am, Thursday, 06'th Aug 2020
In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Atara Biotherapeutics (ATRA – Research
Atara Biotherapeutics Announces Second Quarter 2020 Financial Results and Operational Progress
08:01pm, Wednesday, 05'th Aug 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases
Why Atara Biotherapeutics (ATRA) Might Surprise This Earnings Season
12:19pm, Tuesday, 04'th Aug 2020
Atara Biotherapeutics (ATRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Noble Energy Announces Second Quarter Results
12:00am, Monday, 03'rd Aug 2020
Noble Energy, Inc. (NASDAQ: NBL) (“Noble Energy” or the “Company”) today provided second quarter financial and operating results. “Noble Energy's seco
Atara Biotherapeutics to Announce Second Quarter 2020 Financial Results on Wednesday, August 5, 2020
08:01pm, Wednesday, 29'th Jul 2020
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases, including sol
The Retiree's Dividend Portfolio - Jane's June Update: Record Dividends During COVID-19
07:58pm, Monday, 27'th Jul 2020
Jane's retirement accounts generated a total of $2,047.11 of dividend income for June 2020 vs. $1,561.04 of dividend income for June of 2019.
IPO Update: AlloVir Proposes Terms For $251 Million IPO
12:18pm, Sunday, 26'th Jul 2020
AlloVir intends to raise $251 million in a U.S. IPO of its common stock.
Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade
04:00pm, Tuesday, 21'st Jul 2020
Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
